Archives
-
Armistice Capital Joins Institutional Investors in Targeting Companies with FDA Approval Catalysts
Institutional investors, including Armistice Capital, Point72 Asset Management, and Millennium Management, have concentrated capital around companies with specific FDA timelines, treating regulatory decisions as tradeable events that can move stocks 20% or more overnight.
Latest Research Articles
-
Preparing for Your First Speech Therapy Session: What You Need to Do
-
Millionaire CEO Trampled to Death By His Own Elephant on South African Game Reserve
-
Florida Teen Survives Alligator Attack by 'Punching It in the Head'
-
WHO Sounding Alarm on Global Tobacco Control Amid Ongoing Industry Interference
-
How Gene Editing Could Save Endangered Species from Extinction
-
Oil & Gas Operations: Is Greener Actually Possible?
-
Texas Teen Died After Helping Her Family Escape From Car That Plunged Into Raging Floodwaters
-
Texas Woman Hopped on a Kayak to Escape Floodwaters With Her Dogs: 'I'm Still in Shock'
-
Nature-Based Land Development: How Ecological Restoration Can Guide Urban Growth
-
Life on a Caribbean Campus. What Medical Students Should Know
-
Beyond Dire Wolves: How De-Extinction Technology Could Transform Species Conservation
-
Stem Cell Therapy for Autism: Understanding the Role of Biomarkers
MOST POPULAR
-
Is Yerba Mate Nature's Ozempic? Weighing In Risk Vs. Benefits
-
WATCH: 'Ed the Zebra' Airlifted Home After More than a Week on the Run in Tennessee
-
Enjoying Nature: How Outdoor Activities Can Benefit Children & Teens
-
Texas Woman Hopped on a Kayak to Escape Floodwaters With Her Dogs: 'I'm Still in Shock'
-
How Gene Editing Could Save Endangered Species from Extinction
